Marksans Pharma Limited Stock price

Equities

MARKSANS

INE750C01026

Pharmaceuticals

Market Closed - NSE India S.E. 08:02:00 2024-03-28 am EDT 5-day change 1st Jan Change
151.9 INR +0.60% Intraday chart for Marksans Pharma Limited +8.50% -5.71%
Sales 2024 * 21.58B 259M Sales 2025 * 26.33B 316M Capitalization 68.84B 826M
Net income 2024 * 3.34B 40M Net income 2025 * 4.07B 48.77M EV / Sales 2024 * 3.19 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 2.61 x
P/E ratio 2024 *
20.6 x
P/E ratio 2025 *
16.9 x
Employees 852
Yield 2024 *
-
Yield 2025 *
-
Free-Float 55.99%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.60%
1 week+8.50%
Current month-0.39%
1 month-3.98%
3 months-4.91%
6 months+41.70%
Current year-5.71%
More quotes
1 week
143.05
Extreme 143.05
153.80
1 month
130.25
Extreme 130.25
157.75
Current year
130.25
Extreme 130.25
179.30
1 year
69.55
Extreme 69.55
179.30
3 years
38.60
Extreme 38.6
179.30
5 years
9.85
Extreme 9.85
179.30
10 years
9.85
Extreme 9.85
179.30
More quotes
Managers TitleAgeSince
Chief Executive Officer 52 92-04-15
Director of Finance/CFO 54 02-09-05
Compliance Officer - -
Members of the board TitleAgeSince
Director/Board Member 49 21-08-10
Chief Executive Officer 52 92-04-15
Director/Board Member 52 14-09-24
More insiders
Date Price Change Volume
24-03-28 151.9 +0.60% 697,149
24-03-27 151 +4.64% 1,367,069
24-03-26 144.3 -0.79% 615,831
24-03-22 145.4 +0.38% 907,758
24-03-21 144.9 +3.50% 680,593

Delayed Quote NSE India S.E., March 28, 2024 at 08:02 am EDT

More quotes
Marksans Pharma Limited is an India-based pharmaceutical company. The Company is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations. The Company produces goods across various therapeutic areas, such as pain management, cough and cold, cardiovascular and central nervous system, anti-diabetic, gastrointestinal, hormonal treatment, and anti-allergic, among others. The Company operates four manufacturing facilities across India, the United Kingdom and the United States. The Company manufactures oral solid tablets, soft gelatin capsules and hard capsules in Goa. It also manufactures non-sterile liquids, ointments and powder products and caters to the United Kingdom, West Africa and the Middle East, which is located in the United Kingdom. The Company has spread its facility to over 7000 square meters and manufactures tablets and capsules in the United States.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
151.9
Average target price
-
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Marksans Pharma Limited - NSE India S.E.